Cochrane Briefs
Am Fam Physician. 2005 Oct 1;72(7):1224.
Does a Low Glycemic Index Diet Reduce CHD?
Clinical Question
For patients with risk factors for coronary heart disease (CHD), does a low glycemic index diet reduce heart disease or improve risk factors?
Evidence-Based Answer
There is limited, weak evidence that a low glycemic index diet improves risk factors for CHD, but there are no randomized controlled trials (RCTs) showing a reduction in morbidity or mortality. (SORT rating C)
Practice Pointers
CHD is associated with high fat intake. However, there is uncertainty regarding how rapidly-metabolized dietary carbohydrates may affect the risk for heart attack and stroke. The glycemic index is a measure of the effect of dietary carbohydrate on blood glucose, on a scale from zero to 100; higher numbers correspond to a greater effect.
Kelly and colleagues systematically reviewed RCTs to determine whether a low glycemic index diet decreased mortality or CHD events (patient-oriented outcomes) or had a beneficial effect on risk factors for CHD such as abnormal lipids, glucose metabolism, blood pressure, weight, and clotting factors (surrogate markers that may or may not affect patient outcomes). Fifteen trials lasting four weeks or more were identified. Interventions included dietary advice or a prescribed diet for adult outpatients with at least one major risk factor. None of the studies reported morbidity or mortality. The studies were of poor quality and had too few patients to identify clinically important effects. There was a small reduction in A1C (0.45 percent) and total cholesterol levels (6.6 mg per 100 mL [0.17 mmol per L]). However, these outcomes were not sufficient to recommend low glycemic index diets for patients with risk factors for CHD.
Despite the lack of supporting evidence, several organizations recommend diets rich in complex carbohydrates for patients with risk factors for CHD. The National Cholesterol Education Program (NCEP) recommends that 50 to 60 percent of calories come from foods rich in complex carbohydrates, including grains (especially whole grains), fruits, and vegetables1; this is essentially a low glycemic index diet. The American Dietetic Association supports the dietary recommendations of the NCEP for patients with hyperlipidemia.2 The U.S. Preventive Services Task Force recommends intensive behavioral dietary counseling for adult patients with hyperlipidemia and other known risk factors for cardiovascular disease, but does not specify which diet should be recommended.3
editor’s note: See p. 1154 or http://www.aafp.org/afpsort.xml for SORT information.
Kelly S, et al. Low glycaemic index diets for coronary heart disease. Cochrane Database Syst Rev. 2004;(4):CD004467.
REFERENCES
1. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.
2. American Dietetic Association. Hyperlipidemia medical nutrition therapy protocol. Chicago: American Dietetic Association, 2001.
3. U. S. Preventive Services Task Force. Behavioral counseling in primary care to promote a healthy diet: recommendations and rationale. Am J Prev Med. 2003;24:93–100.
Lower- vs. Higher-Dose Estrogen for Contraception
Clinical Question
Compared with higher-dose pills, are combination oral contraceptives with 20 mcg of estrogen (ethinyl estradiol) equally effective and well tolerated?
Evidence-Based Answer
Although no difference in effectiveness has been demonstrated in existing trials, too few patients have been studied to detect small but clinically important differences in pregnancy rates. Low-dose estrogen pills have higher rates of discontinuation and bleeding disturbances.
Practice Pointers
Although complications are rare with these pills, combination oral contraceptives have been linked to breast cancer, cerebral vascular complications, thrombosis, and myocardial infarction. Therefore, many physicians and patients prefer to use the lowest-dose pill that will provide adequate cycle control and effectiveness.
Gallo and colleagues reviewed the literature to determine how pills containing 20 mcg of ethinyl estradiol compare with higher-dose pills. They found 69 randomized controlled trials. Most trials followed patients for six to 12 cycles. The trials varied in dose of estrogen and in type and dose of progesterone; therefore, meta-analysis was not possible. No trial found a difference in contraceptive effectiveness; however, because pregnancy in women who take oral contraceptives is uncommon, the studies were insufficiently powered to show such a difference. In many of the lower-dose groups, early discontinuation occurred because of amenorrhea, adverse events, or bleeding irregularities. More specific information about which pills are most effective or which estrogen-progestin combinations have the fewest bleeding problems could not be determined. Furthermore, it could not be determined whether lower-dose estrogen pills have the same advantages as higher-dose pills for prevention of ovarian and endometrial cancer and reduction of acne.
Current data indicate disadvantages, but no clear advantages, to combined contraceptive pills with 20 mcg of estrogen. Therefore, it is reasonable to prescribe pills with more than 20 mcg of ethinyl estradiol for most women. The American College of Obstetricians and Gynecologists (ACOG) finds little or no increased risk of oral contraceptives for women with fibroadenoma, benign breast disease with epithelial hyperplasia with or without atypia, or a family history of breast cancer.1 ACOG recommends progesterone-only pills for lactating women and those with increased risk of thromboembolism. Caution should be used when prescribing combination pills for women older than 35 years who smoke. ACOG recommends pills with less than 35 mcg of estrogen for women younger than 35 years who have hypertension.1
For all women, the best form of birth control is the one that will be used consistently. For women who wish to reduce side effects and have regular periods, pills with 30 to 35 mcg of ethinyl estradiol may be a better choice than those with only 20 mcg.
Gallo MF, et al. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2004;(4):CD003989.
REFERENCE
1. ACOG Practice Bulletin no. 18, July 2000. The use of hormonal contraception in women with coexisting medical conditions. Washington, D.C.: American College of Obstetricians and Gynecologists, 2000.
The series coordinator for AFP is Clarissa Kripke, M.D., Department of Family and Community Medicine, University of California, San Francisco.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact
afpserv@aafp.org for copyright questions and/or permission requests.
AFP Home
| About Us | Contact Us | Subscribe | AFP by E-Mail
| Permissions
About Online Access |
Employment Opportunities
Information for: Authors |
Advertisers
PUBMED:
• Citation
More in AFP:
• Contraception (13)
• Contraceptives, Oral, Combined (8)
• Estrogens (13)
• Ethinyl Estradiol (2)
